Medgend Icon







discontinued


Calderol FDA Approved Drugs

RAYALDEE [CalcifediolC27H44O2H2O]
RX
-
0.03mg (oral capsule, extended release)
Opko Ireland GlobalJun 17, 2016
  • Administration of 25-hydroxyvitamin d3 by controlled release.
  • Treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease using controlled release, oral 25-hydroxyvitamin d.
  • Use of controlled release 25-hydroxyvitamin d in treating secondary hyperparathyroidism in patients having chronic kidney disease.
  • Use of extended release oral 25-hydroxyvitamin d3 in treating secondary hyperparathyroidism in adult patients having chronic kidney disease stage 3 or stage 4.
  • Use of sustained release 25-hydroxyvitamin d in treating patients having 25-hydroxyvitamin d insufficiency or deficiency.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.